These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 19749671

  • 1. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F, Vaccaro V.
    Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of progesterone action in inhibiting prematurity.
    Sfakianaki AK, Norwitz ER.
    J Matern Fetal Neonatal Med; 2006 Dec; 19(12):763-72. PubMed ID: 17190686
    [Abstract] [Full Text] [Related]

  • 3. From concept to practice: the recent history of preterm delivery prevention. Part II: Subclinical infection and hormonal effects.
    Vidaeff AC, Ramin SM.
    Am J Perinatol; 2006 Feb; 23(2):75-84. PubMed ID: 16506112
    [Abstract] [Full Text] [Related]

  • 4. 17 hydroxyprogesterone for the prevention of preterm delivery.
    Meis PJ, Society for Maternal-Fetal Medicine.
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
    [Abstract] [Full Text] [Related]

  • 5. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
    Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ, Saltzman DH.
    Am J Obstet Gynecol; 2007 Mar; 196(3):224.e1-4. PubMed ID: 17346529
    [Abstract] [Full Text] [Related]

  • 6. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S.
    Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
    [Abstract] [Full Text] [Related]

  • 7. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ.
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [Abstract] [Full Text] [Related]

  • 8. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbrière R, Perrotin F, Bohec C, Connan L, Vayssière C, Langer B, Mantel A, Azimi S, Porcher R, Azria E, Groupe De Recherche En Obstétrique et Gynécologie.
    Am J Obstet Gynecol; 2012 Mar; 206(3):206.e1-9. PubMed ID: 22381603
    [Abstract] [Full Text] [Related]

  • 9. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR.
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [Abstract] [Full Text] [Related]

  • 10. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
    Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    N Engl J Med; 2003 Jun 12; 348(24):2379-85. PubMed ID: 12802023
    [Abstract] [Full Text] [Related]

  • 11. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
    Ventolini G, Duke J, Po W, Barhan S, Rhea D, Desch C, Istwan N, Stanziano G.
    J Reprod Med; 2008 Sep 12; 53(9):667-71. PubMed ID: 18839818
    [Abstract] [Full Text] [Related]

  • 12. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2007 Sep 12; 197(3):262.e1-4. PubMed ID: 17826412
    [Abstract] [Full Text] [Related]

  • 13. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
    Rittenberg C, Newman RB, Istwan NB, Rhea DJ, Stanziano GJ.
    J Reprod Med; 2009 Feb 12; 54(2):47-52. PubMed ID: 19301566
    [Abstract] [Full Text] [Related]

  • 14. 17alpha-hydroxy-progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery.
    Facchinetti F, Dante G, Venturini P, Paganelli S, Volpe A.
    Am J Perinatol; 2008 Sep 12; 25(8):503-6. PubMed ID: 18756431
    [Abstract] [Full Text] [Related]

  • 15. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM, Lewis DF.
    Am J Obstet Gynecol; 2016 Jan 12; 214(1):45-56. PubMed ID: 26558340
    [Abstract] [Full Text] [Related]

  • 16. Recurrent hope for the treatment of preterm delivery.
    Doggrell SA.
    Expert Opin Pharmacother; 2003 Dec 12; 4(12):2363-6. PubMed ID: 14640934
    [Abstract] [Full Text] [Related]

  • 17. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
    Saccone G, Suhag A, Berghella V.
    Am J Obstet Gynecol; 2015 Jul 12; 213(1):16-22. PubMed ID: 25659469
    [Abstract] [Full Text] [Related]

  • 18. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
    Mason MV, Poole-Yaeger A, Krueger CR, House KM, Lucas B.
    Manag Care; 2010 Feb 12; 19(2):46-52. PubMed ID: 20550052
    [Abstract] [Full Text] [Related]

  • 19. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
    Rebarber A, Cleary-Goldman J, Istwan NB, Rhea DJ, Desch C, Russo-Stieglitz K, Saltzman DH.
    Am J Perinatol; 2008 May 12; 25(5):271-5. PubMed ID: 18401840
    [Abstract] [Full Text] [Related]

  • 20. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, Schwarz RH, Damus K.
    Obstet Gynecol; 2005 Feb 12; 105(2):267-72. PubMed ID: 15684150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.